PolyPid (PYPD) - Total Liabilities
Based on the latest financial reports, PolyPid (PYPD) has total liabilities worth $11.33 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PolyPid operating cash flow efficiency to assess how effectively this company generates cash.
PolyPid - Total Liabilities Trend (2012–2025)
This chart illustrates how PolyPid's total liabilities have evolved over time, based on quarterly financial data. Check PolyPid liquid asset ratio to evaluate the company's liquid asset resilience ratio.
PolyPid Competitors by Total Liabilities
The table below lists competitors of PolyPid ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inmax Holding Co Ltd
TWO:1591
|
Taiwan | NT$49.40 Million |
|
GreenMobility A/S
CO:GREENM
|
Denmark | Dkr139.33 Million |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
India | Rs943.42 Million |
|
Pender Growth Fund VCC Inc
V:PTF
|
Canada | CA$691.71K |
|
Huvis Corporation
KO:079980
|
Korea | ₩501.60 Billion |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
USA | $2.49 Million |
|
South West Pinnacle Exploration Limited
NSE:SOUTHWEST
|
India | Rs1.40 Billion |
|
SanDi Properties Co Ltd
TW:1438
|
Taiwan | NT$11.29 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down PolyPid's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of PolyPid.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PolyPid's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PolyPid (2012–2025)
The table below shows the annual total liabilities of PolyPid from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.33 Million | -35.37% |
| 2024-12-31 | $17.54 Million | +0.39% |
| 2023-12-31 | $17.47 Million | -13.28% |
| 2022-12-31 | $20.14 Million | +143.41% |
| 2021-12-31 | $8.28 Million | +169.54% |
| 2020-12-31 | $3.07 Million | +8.48% |
| 2019-12-31 | $2.83 Million | -97.06% |
| 2018-12-31 | $96.19 Million | -13.83% |
| 2017-12-31 | $111.63 Million | +109.85% |
| 2016-12-31 | $53.20 Million | +1862.23% |
| 2015-12-31 | $2.71 Million | -72.94% |
| 2013-12-31 | $10.02 Million | +64.30% |
| 2012-12-31 | $6.10 Million | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more